Ocugen Inc (OCGN)

[vieuxcarre]

What happened to your multi bagger

[harry crumb]

Then what? Let the ATM begin an dilution. We see this as a 1.25/1.50 pps stock without any real positive news on fda approvals or new science trials

[sgunderbarth]

“The Company believes that its current cash and cash equivalents balance will enable it to fund its operations into the second quarter of 2023.”


https://ir.ocugen.com/news-releases/news-release-details/ocugen-provides-business-update-second-quarter-2022-financial

OCGN

[Sideem]

Hmm. If they're announcing the earnings for Q2 early tomorrow, maybe that means it's good news.

[sgunderbarth]

Holding

OCGN

[harry crumb]

Possible multi bagger here is what could happen

[harry crumb]

17.65 52 week high, on some positive news this rips folks

[harry crumb]

We are here an adding, $4 pps is a safe an reasonable target imo

[vieuxcarre]

Quad witching for options.

[heyitsmeagain]

Huge buy

[conix]

Ocugen, Inc. Announces Issuance of U.S. Patent for Treating Retinal Degenerative Diseases Using ...

MALVERN, Pa., June 13, 2022 (GLOBE NEWSWIRE) -- Ocugen, Inc. (NASDAQ:OCGN), a clinical-stage biopharmaceutical company focused on discovering, developing, and commercializing novel gene and cell therapies, biologicals, and vaccines, today announced that on June 7, 2022, the United States Patent and Trademark Office (“USPTO”) issued U.S. Patent No. 11,351,225, which is directed to methods for preventing or treating an ocular disease or disorder associated with a retinal degenerative disease.

U.S. Patent No. 11,351,225 (the “‘225 Patent”) covers the use of a nuclear hormone receptor gene, such as NR2E3, RORA, NUPR1, and NR2C1, in treating retinal degenerative diseases as well as reducing the risk of developing such diseases. Additional issued claims pertain to using a nuclear hormone receptor gene to treat retinitis pigmentosa, age-related macular degeneration, and inherited retinal degenerative diseases. The ‘225 Patent contains 18 claims and expires in March 2034.

“We are pleased to have been granted this new U.S. patent through our exclusive license agreement with The Schepens Eye Research Institute, an affiliate of Harvard Medical School. We believe this patent significantly validates our modifier gene therapy platform developed by Dr. Neena Haider and augments our growing global patent portfolio,” commented Dr. Shankar Musunuri, Chairman, CEO, and Co-Founder of Ocugen.

This newly allowed patent is exclusive to Ocugen and is the latest U.S. patent issued in connection with Ocugen’s gene therapy program for treating retinal degenerative diseases.

About Ocugen, Inc.

Ocugen, Inc. is a biotechnology company focused on discovering, developing, and commercializing novel gene and cell therapies, biologicals and vaccines that improve health and offer hope for people and global communities. We are making an impact through courageous innovation, taking science in new directions in service of patients. Our breakthrough modifier gene therapy platform has the potential to treat multiple diseases with one drug and we are advancing research in other therapeutic areas to offer new options for people with unmet medical needs. Discover more at www.ocugen.com and follow us on Twitter and LinkedIn.

Cautionary Note on Forward-Looking Statements

This press release contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995, which are subject to risks and uncertainties. We may, in some cases, use terms such as “predicts,” “believes,” “potential,” “proposed,” “continue,” “estimates,” “anticipates,” “expects,” “plans,” “intends,” “may,” “could,” “might,” “will,” “should” or other words that convey uncertainty of future events or outcomes to identify these forward-looking statements. Such statements are subject to numerous important factors, risks and uncertainties that may cause actual events or results to differ materially from our current expectations. These and other risks and uncertainties are more fully described in our periodic filings with the Securities and Exchange Commission (“SEC”), including the risk factors described in the section entitled “Risk Factors” in the quarterly and annual reports that we file with the SEC. Any forward-looking statements that we make in this press release speak only as of the date of this press release. Except as required by law, we assume no obligation to update forward-looking statements contained in this press release whether as a result of new information, future events or otherwise, after the date of this press release.

Contact

Tiberend Strategic Advisors, Inc.

Jonathan Nugent / Daniel Kontoh-Boateng (Investors)

[investingnotgambling]

How much is ocugen paying for postage? I have been getting a piece in the mail every day for two weeks regarding the annual meeting. Today it looks like I’m getting three.

[joetho]

News this morning. Also a related 8k, link here:
FDA hold lifted

https://last10k.com/sec-filings/ocgn/0001104659-22-063664.htm?utm_source=stocktwits&utm_medium=forum&utm_campaign=8K&utm_term=ocgn

[DBWV]

Higher and higher ????

[sgunderbarth]

Holding

OCGN

[1hunglo]

GO,GO,GO OCGN NOW IN MEXICO!!!HOLDEN THE GOLDEN.

[1hunglo]

OCGN Definitely NOT a One Trick Pony $$$$

[sgunderbarth]

Holding

OCGN

[conix]

OCGN chart,,,things that make you go Hmmmm...

[beambe]

only if you invest now - buy before the NEWS

[stockdawg44]

Been a great swing, flip play here for a couple months.

[Sideem]

Congrats...*LOL*. My breakeven is $6.06. Will it reach there at minimum is anybody's guess.

[lizzy241]

OMG I'm almost even...lol

[stockdawg44]

$4.32 OCGN!

[lizzy241]

Plus another block of 11,414,800 @3.72 first trade was red and the last was green..... Ummm????

[beambe]

okay

[stockdawg44]

11.4 MIL @ $3.72, might be a good Monday

[stockdawg44]

14.3 Million @ $3.72 @ close, 1 trade.....OCGN not bad

[beambe]

if not now then when

[beambe]

buy them today before the News

[sgunderbarth]

Holding

OCGN

[kingsransome]

buy volume is crazy $$$$$$ what a nice dipperrrrrr mhop

[starkd748]

I did say 2ss

[SBL321]

I'm not mad at today at all I saw it recover nice since the news.
However am I p'ed off that I put more money in at $4 last week to average down heck yea. I wish it was today ... lesson learned hold out for news good or bad. Watch this get Canadian approval the same day the USA denies it. we will be right back at $4 haha where we started <--- no just kidding that won't happen.

[kingsransome]

i've been trading this for years,seen how and when to grab the opportunities thats all,not in love with any trades

[maximumgriff]

Oh wow, you’re just as delusional as those stocktwit peeps

[kingsransome]

no shitz,,they have been and still are working on that,look at their pipline meanwhile

[maximumgriff]

Dude, they just got denial EUA for children vaccine. What are you smoking?

[kingsransome]

buyin the dip,,lol,,they are still working with the fda for children,ocgn has a big pipeline no sweat at these prices,,mhop $$$

[maximumgriff]

Game over for this ticker, EUA denied!

[nsomniyak]

What do you expect to hear?

[beambe]

Awesome NEWS tomorrow

[beambe]

https://ocugen.com/pipeline/overview/

[beambe]

buy before the n
News

[beambe]

According to a post in yahoo.finance on the future of Ocugen's Covaxin, Health Canada is said to have said it will undergo accelerated testing of the vaccine.

[SBL321]

Am I seeing the beautiful Morning Star Pattern? this show is about to start ...buckle up, get the popcorn and watch the MM's Hedgies and Shorties burn.

[Sideem]

The market agrees...so far.

[beambe]

Q4 is good

[WealthyKing]

$ocgn offering expected to close this week. Looking forward to recouping the gains we all saw yesterday before the news. $6-8 target exit for me. Hopefully before end of March. Need to move this over to $seed before it takes off

[stockdawg44]

great flipping liquidity....catch it.